Click for best price
Raibizumab Biosimilars Market Size, Share 2023
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.
This report aims to provide a comprehensive presentation of the global market for Raibizumab Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Raibizumab Biosimilars. This report contains market size and forecasts of Raibizumab Biosimilars in global, including the following market information:
Global Raibizumab Biosimilars Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global Raibizumab Biosimilars Market Sales, 2018-2023, 2024-2032, (K Units)
Global top five Raibizumab Biosimilars companies in 2022 (%)
The global Raibizumab Biosimilars market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
AMD Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Raibizumab Biosimilars include Roche, Novartis, Genentech, Pfizer, Sartorius, Eli Lilly, Bayer, Amgen and PlantForm, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Raibizumab Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Raibizumab Biosimilars Market, by Type, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Raibizumab Biosimilars Market Segment Percentages, by Type, 2022 (%)
AMD
CNV
DME
Global Raibizumab Biosimilars Market, by Application, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Raibizumab Biosimilars Market Segment Percentages, by Application, 2022 (%)
ARMD
Diabetic Retinopathy
Macular Edema
Global Raibizumab Biosimilars Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Raibizumab Biosimilars Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Raibizumab Biosimilars revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Raibizumab Biosimilars revenues share in global market, 2022 (%)
Key companies Raibizumab Biosimilars sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Raibizumab Biosimilars sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Novartis
Genentech
Pfizer
Sartorius
Eli Lilly
Bayer
Amgen
PlantForm
PharmaPraxis
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy's
Aurobindo Pharma
Biocad
MAbxience
Hetero
Biocon
Kirin Biologics
Mylan
BeiGene
Innovent
Qilu Pharmaceutical
Hengrui Pharmaceuticals
Hisun Pharmaceutical
TOT BIOPHARM
Luye Pharmaceutical
Henlius
Outline of Major Chapters:
Chapter 1: Introduces the definition of Raibizumab Biosimilars, market overview.
Chapter 2: Global Raibizumab Biosimilars market size in revenue and volume.
Chapter 3: Detailed analysis of Raibizumab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Raibizumab Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Raibizumab Biosimilars capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Raibizumab Biosimilars Market, Global Outlook and Forecast 2023-2032 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
127 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Raibizumab Biosimilars Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Raibizumab Biosimilars Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Raibizumab Biosimilars Overall Market Size
2.1 Global Raibizumab Biosimilars Market Size: 2022 VS 2032
2.2 Global Raibizumab Biosimilars Revenue, Prospects & Forecasts: 2018-2032
2.3 Global Raibizumab Biosimilars Sales: 2018-2032
3 Company Landscape
3.1 Top Raibizumab Biosimilars Players in Global Market
3.2 Top Global Raibizumab Biosimilars Companies Ranked by Revenue
3.3 Global Raibizumab Biosimilars Revenue by Companies
3.4 Global Raibizumab Biosimilars Sales by Companies
3.5 Global Raibizumab Biosimilars Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Raibizumab Biosimilars Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Raibizumab Biosimilars Product Type
3.8 Tier 1, Tier 2 and Tier 3 Raibizumab Biosimilars Players in Global Market
3.8.1 List of Global Tier 1 Raibizumab Biosimilars Companies
3.8.2 List of Global Tier 2 and Tier 3 Raibizumab Biosimilars Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Raibizumab Biosimilars Market Size Markets, 2022 & 2032
4.1.2 AMD
4.1.3 CNV
4.1.4 DME
4.2 By Type - Global Raibizumab Biosimilars Revenue & Forecasts
4.2.1 By Type - Global Raibizumab Biosimilars Revenue, 2018-2023
4.2.2 By Type - Global Raibizumab Biosimilars Revenue, 2024-2032
4.2.3 By Type - Global Raibizumab Biosimilars Revenue Market Share, 2018-2032
4.3 By Type - Global Raibizumab Biosimilars Sales & Forecasts
4.3.1 By Type - Global Raibizumab Biosimilars Sales, 2018-2023
4.3.2 By Type - Global Raibizumab Biosimilars Sales, 2024-2032
4.3.3 By Type - Global Raibizumab Biosimilars Sales Market Share, 2018-2032
4.4 By Type - Global Raibizumab Biosimilars Price (Manufacturers Selling Prices), 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Raibizumab Biosimilars Market Size, 2022 & 2032
5.1.2 ARMD
5.1.3 Diabetic Retinopathy
5.1.4 Macular Edema
5.2 By Application - Global Raibizumab Biosimilars Revenue & Forecasts
5.2.1 By Application - Global Raibizumab Biosimilars Revenue, 2018-2023
5.2.2 By Application - Global Raibizumab Biosimilars Revenue, 2024-2032
5.2.3 By Application - Global Raibizumab Biosimilars Revenue Market Share, 2018-2032
5.3 By Application - Global Raibizumab Biosimilars Sales & Forecasts
5.3.1 By Application - Global Raibizumab Biosimilars Sales, 2018-2023
5.3.2 By Application - Global Raibizumab Biosimilars Sales, 2024-2032
5.3.3 By Application - Global Raibizumab Biosimilars Sales Market Share, 2018-2032
5.4 By Application - Global Raibizumab Biosimilars Price (Manufacturers Selling Prices), 2018-2032
6 Sights by Region
6.1 By Region - Global Raibizumab Biosimilars Market Size, 2022 & 2032
6.2 By Region - Global Raibizumab Biosimilars Revenue & Forecasts
6.2.1 By Region - Global Raibizumab Biosimilars Revenue, 2018-2023
6.2.2 By Region - Global Raibizumab Biosimilars Revenue, 2024-2032
6.2.3 By Region - Global Raibizumab Biosimilars Revenue Market Share, 2018-2032
6.3 By Region - Global Raibizumab Biosimilars Sales & Forecasts
6.3.1 By Region - Global Raibizumab Biosimilars Sales, 2018-2023
6.3.2 By Region - Global Raibizumab Biosimilars Sales, 2024-2032
6.3.3 By Region - Global Raibizumab Biosimilars Sales Market Share, 2018-2032
6.4 North America
6.4.1 By Country - North America Raibizumab Biosimilars Revenue, 2018-2032
6.4.2 By Country - North America Raibizumab Biosimilars Sales, 2018-2032
6.4.3 US Raibizumab Biosimilars Market Size, 2018-2032
6.4.4 Canada Raibizumab Biosimilars Market Size, 2018-2032
6.4.5 Mexico Raibizumab Biosimilars Market Size, 2018-2032
6.5 Europe
6.5.1 By Country - Europe Raibizumab Biosimilars Revenue, 2018-2032
6.5.2 By Country - Europe Raibizumab Biosimilars Sales, 2018-2032
6.5.3 Germany Raibizumab Biosimilars Market Size, 2018-2032
6.5.4 France Raibizumab Biosimilars Market Size, 2018-2032
6.5.5 U.K. Raibizumab Biosimilars Market Size, 2018-2032
6.5.6 Italy Raibizumab Biosimilars Market Size, 2018-2032
6.5.7 Russia Raibizumab Biosimilars Market Size, 2018-2032
6.5.8 Nordic Countries Raibizumab Biosimilars Market Size, 2018-2032
6.5.9 Benelux Raibizumab Biosimilars Market Size, 2018-2032
6.6 Asia
6.6.1 By Region - Asia Raibizumab Biosimilars Revenue, 2018-2032
6.6.2 By Region - Asia Raibizumab Biosimilars Sales, 2018-2032
6.6.3 China Raibizumab Biosimilars Market Size, 2018-2032
6.6.4 Japan Raibizumab Biosimilars Market Size, 2018-2032
6.6.5 South Korea Raibizumab Biosimilars Market Size, 2018-2032
6.6.6 Southeast Asia Raibizumab Biosimilars Market Size, 2018-2032
6.6.7 India Raibizumab Biosimilars Market Size, 2018-2032
6.7 South America
6.7.1 By Country - South America Raibizumab Biosimilars Revenue, 2018-2032
6.7.2 By Country - South America Raibizumab Biosimilars Sales, 2018-2032
6.7.3 Brazil Raibizumab Biosimilars Market Size, 2018-2032
6.7.4 Argentina Raibizumab Biosimilars Market Size, 2018-2032
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Raibizumab Biosimilars Revenue, 2018-2032
6.8.2 By Country - Middle East & Africa Raibizumab Biosimilars Sales, 2018-2032
6.8.3 Turkey Raibizumab Biosimilars Market Size, 2018-2032
6.8.4 Israel Raibizumab Biosimilars Market Size, 2018-2032
6.8.5 Saudi Arabia Raibizumab Biosimilars Market Size, 2018-2032
6.8.6 UAE Raibizumab Biosimilars Market Size, 2018-2032
7 Manufacturers & Brands Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Raibizumab Biosimilars Major Product Offerings
7.1.4 Roche Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.1.5 Roche Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Raibizumab Biosimilars Major Product Offerings
7.2.4 Novartis Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Genentech
7.3.1 Genentech Company Summary
7.3.2 Genentech Business Overview
7.3.3 Genentech Raibizumab Biosimilars Major Product Offerings
7.3.4 Genentech Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.3.5 Genentech Key News & Latest Developments
7.4 Pfizer
7.4.1 Pfizer Company Summary
7.4.2 Pfizer Business Overview
7.4.3 Pfizer Raibizumab Biosimilars Major Product Offerings
7.4.4 Pfizer Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.4.5 Pfizer Key News & Latest Developments
7.5 Sartorius
7.5.1 Sartorius Company Summary
7.5.2 Sartorius Business Overview
7.5.3 Sartorius Raibizumab Biosimilars Major Product Offerings
7.5.4 Sartorius Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.5.5 Sartorius Key News & Latest Developments
7.6 Eli Lilly
7.6.1 Eli Lilly Company Summary
7.6.2 Eli Lilly Business Overview
7.6.3 Eli Lilly Raibizumab Biosimilars Major Product Offerings
7.6.4 Eli Lilly Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.6.5 Eli Lilly Key News & Latest Developments
7.7 Bayer
7.7.1 Bayer Company Summary
7.7.2 Bayer Business Overview
7.7.3 Bayer Raibizumab Biosimilars Major Product Offerings
7.7.4 Bayer Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.7.5 Bayer Key News & Latest Developments
7.8 Amgen
7.8.1 Amgen Company Summary
7.8.2 Amgen Business Overview
7.8.3 Amgen Raibizumab Biosimilars Major Product Offerings
7.8.4 Amgen Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.8.5 Amgen Key News & Latest Developments
7.9 PlantForm
7.9.1 PlantForm Company Summary
7.9.2 PlantForm Business Overview
7.9.3 PlantForm Raibizumab Biosimilars Major Product Offerings
7.9.4 PlantForm Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.9.5 PlantForm Key News & Latest Developments
7.10 PharmaPraxis
7.10.1 PharmaPraxis Company Summary
7.10.2 PharmaPraxis Business Overview
7.10.3 PharmaPraxis Raibizumab Biosimilars Major Product Offerings
7.10.4 PharmaPraxis Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.10.5 PharmaPraxis Key News & Latest Developments
7.11 Samsung Bioepis
7.11.1 Samsung Bioepis Company Summary
7.11.2 Samsung Bioepis Raibizumab Biosimilars Business Overview
7.11.3 Samsung Bioepis Raibizumab Biosimilars Major Product Offerings
7.11.4 Samsung Bioepis Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.11.5 Samsung Bioepis Key News & Latest Developments
7.12 Centus
7.12.1 Centus Company Summary
7.12.2 Centus Raibizumab Biosimilars Business Overview
7.12.3 Centus Raibizumab Biosimilars Major Product Offerings
7.12.4 Centus Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.12.5 Centus Key News & Latest Developments
7.13 Cadila Pharmaceuticals
7.13.1 Cadila Pharmaceuticals Company Summary
7.13.2 Cadila Pharmaceuticals Raibizumab Biosimilars Business Overview
7.13.3 Cadila Pharmaceuticals Raibizumab Biosimilars Major Product Offerings
7.13.4 Cadila Pharmaceuticals Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.13.5 Cadila Pharmaceuticals Key News & Latest Developments
7.14 Dr Reddy's
7.14.1 Dr Reddy's Company Summary
7.14.2 Dr Reddy's Business Overview
7.14.3 Dr Reddy's Raibizumab Biosimilars Major Product Offerings
7.14.4 Dr Reddy's Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.14.5 Dr Reddy's Key News & Latest Developments
7.15 Aurobindo Pharma
7.15.1 Aurobindo Pharma Company Summary
7.15.2 Aurobindo Pharma Business Overview
7.15.3 Aurobindo Pharma Raibizumab Biosimilars Major Product Offerings
7.15.4 Aurobindo Pharma Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.15.5 Aurobindo Pharma Key News & Latest Developments
7.16 Biocad
7.16.1 Biocad Company Summary
7.16.2 Biocad Business Overview
7.16.3 Biocad Raibizumab Biosimilars Major Product Offerings
7.16.4 Biocad Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.16.5 Biocad Key News & Latest Developments
7.17 MAbxience
7.17.1 MAbxience Company Summary
7.17.2 MAbxience Business Overview
7.17.3 MAbxience Raibizumab Biosimilars Major Product Offerings
7.17.4 MAbxience Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.17.5 MAbxience Key News & Latest Developments
7.18 Hetero
7.18.1 Hetero Company Summary
7.18.2 Hetero Business Overview
7.18.3 Hetero Raibizumab Biosimilars Major Product Offerings
7.18.4 Hetero Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.18.5 Hetero Key News & Latest Developments
7.19 Biocon
7.19.1 Biocon Company Summary
7.19.2 Biocon Business Overview
7.19.3 Biocon Raibizumab Biosimilars Major Product Offerings
7.19.4 Biocon Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.19.5 Biocon Key News & Latest Developments
7.20 Kirin Biologics
7.20.1 Kirin Biologics Company Summary
7.20.2 Kirin Biologics Business Overview
7.20.3 Kirin Biologics Raibizumab Biosimilars Major Product Offerings
7.20.4 Kirin Biologics Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.20.5 Kirin Biologics Key News & Latest Developments
7.21 Mylan
7.21.1 Mylan Company Summary
7.21.2 Mylan Business Overview
7.21.3 Mylan Raibizumab Biosimilars Major Product Offerings
7.21.4 Mylan Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.21.5 Mylan Key News & Latest Developments
7.22 BeiGene
7.22.1 BeiGene Company Summary
7.22.2 BeiGene Business Overview
7.22.3 BeiGene Raibizumab Biosimilars Major Product Offerings
7.22.4 BeiGene Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.22.5 BeiGene Key News & Latest Developments
7.23 Innovent
7.23.1 Innovent Company Summary
7.23.2 Innovent Business Overview
7.23.3 Innovent Raibizumab Biosimilars Major Product Offerings
7.23.4 Innovent Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.23.5 Innovent Key News & Latest Developments
7.24 Qilu Pharmaceutical
7.24.1 Qilu Pharmaceutical Company Summary
7.24.2 Qilu Pharmaceutical Business Overview
7.24.3 Qilu Pharmaceutical Raibizumab Biosimilars Major Product Offerings
7.24.4 Qilu Pharmaceutical Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.24.5 Qilu Pharmaceutical Key News & Latest Developments
7.25 Hengrui Pharmaceuticals
7.25.1 Hengrui Pharmaceuticals Company Summary
7.25.2 Hengrui Pharmaceuticals Business Overview
7.25.3 Hengrui Pharmaceuticals Raibizumab Biosimilars Major Product Offerings
7.25.4 Hengrui Pharmaceuticals Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.25.5 Hengrui Pharmaceuticals Key News & Latest Developments
7.26 Hisun Pharmaceutical
7.26.1 Hisun Pharmaceutical Company Summary
7.26.2 Hisun Pharmaceutical Business Overview
7.26.3 Hisun Pharmaceutical Raibizumab Biosimilars Major Product Offerings
7.26.4 Hisun Pharmaceutical Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.26.5 Hisun Pharmaceutical Key News & Latest Developments
7.27 TOT BIOPHARM
7.27.1 TOT BIOPHARM Company Summary
7.27.2 TOT BIOPHARM Business Overview
7.27.3 TOT BIOPHARM Raibizumab Biosimilars Major Product Offerings
7.27.4 TOT BIOPHARM Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.27.5 TOT BIOPHARM Key News & Latest Developments
7.28 Luye Pharmaceutical
7.28.1 Luye Pharmaceutical Company Summary
7.28.2 Luye Pharmaceutical Business Overview
7.28.3 Luye Pharmaceutical Raibizumab Biosimilars Major Product Offerings
7.28.4 Luye Pharmaceutical Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.28.5 Luye Pharmaceutical Key News & Latest Developments
7.29 Henlius
7.29.1 Henlius Company Summary
7.29.2 Henlius Business Overview
7.29.3 Henlius Raibizumab Biosimilars Major Product Offerings
7.29.4 Henlius Raibizumab Biosimilars Sales and Revenue in Global (2018-2023)
7.29.5 Henlius Key News & Latest Developments
8 Global Raibizumab Biosimilars Production Capacity, Analysis
8.1 Global Raibizumab Biosimilars Production Capacity, 2018-2032
8.2 Raibizumab Biosimilars Production Capacity of Key Manufacturers in Global Market
8.3 Global Raibizumab Biosimilars Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Raibizumab Biosimilars Supply Chain Analysis
10.1 Raibizumab Biosimilars Industry Value Chain
10.2 Raibizumab Biosimilars Upstream Market
10.3 Raibizumab Biosimilars Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Raibizumab Biosimilars Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Raibizumab Biosimilars in Global Market
Table 2. Top Raibizumab Biosimilars Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Raibizumab Biosimilars Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Raibizumab Biosimilars Revenue Share by Companies, 2018-2023
Table 5. Global Raibizumab Biosimilars Sales by Companies, (K Units), 2018-2023
Table 6. Global Raibizumab Biosimilars Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Raibizumab Biosimilars Price (2018-2023) & (K USD/Unit)
Table 8. Global Manufacturers Raibizumab Biosimilars Product Type
Table 9. List of Global Tier 1 Raibizumab Biosimilars Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Raibizumab Biosimilars Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Raibizumab Biosimilars Revenue, (US$, Mn), 2022 & 2032
Table 12. By Type - Global Raibizumab Biosimilars Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Raibizumab Biosimilars Revenue (US$, Mn), 2024-2032
Table 14. By Type - Global Raibizumab Biosimilars Sales (K Units), 2018-2023
Table 15. By Type - Global Raibizumab Biosimilars Sales (K Units), 2024-2032
Table 16. By Application ? Global Raibizumab Biosimilars Revenue, (US$, Mn), 2022 & 2032
Table 17. By Application - Global Raibizumab Biosimilars Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Raibizumab Biosimilars Revenue (US$, Mn), 2024-2032
Table 19. By Application - Global Raibizumab Biosimilars Sales (K Units), 2018-2023
Table 20. By Application - Global Raibizumab Biosimilars Sales (K Units), 2024-2032
Table 21. By Region ? Global Raibizumab Biosimilars Revenue, (US$, Mn), 2022 VS 2032
Table 22. By Region - Global Raibizumab Biosimilars Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Raibizumab Biosimilars Revenue (US$, Mn), 2024-2032
Table 24. By Region - Global Raibizumab Biosimilars Sales (K Units), 2018-2023
Table 25. By Region - Global Raibizumab Biosimilars Sales (K Units), 2024-2032
Table 26. By Country - North America Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Raibizumab Biosimilars Revenue, (US$, Mn), 2024-2032
Table 28. By Country - North America Raibizumab Biosimilars Sales, (K Units), 2018-2023
Table 29. By Country - North America Raibizumab Biosimilars Sales, (K Units), 2024-2032
Table 30. By Country - Europe Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Raibizumab Biosimilars Revenue, (US$, Mn), 2024-2032
Table 32. By Country - Europe Raibizumab Biosimilars Sales, (K Units), 2018-2023
Table 33. By Country - Europe Raibizumab Biosimilars Sales, (K Units), 2024-2032
Table 34. By Region - Asia Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Raibizumab Biosimilars Revenue, (US$, Mn), 2024-2032
Table 36. By Region - Asia Raibizumab Biosimilars Sales, (K Units), 2018-2023
Table 37. By Region - Asia Raibizumab Biosimilars Sales, (K Units), 2024-2032
Table 38. By Country - South America Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Raibizumab Biosimilars Revenue, (US$, Mn), 2024-2032
Table 40. By Country - South America Raibizumab Biosimilars Sales, (K Units), 2018-2023
Table 41. By Country - South America Raibizumab Biosimilars Sales, (K Units), 2024-2032
Table 42. By Country - Middle East & Africa Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Raibizumab Biosimilars Revenue, (US$, Mn), 2024-2032
Table 44. By Country - Middle East & Africa Raibizumab Biosimilars Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Raibizumab Biosimilars Sales, (K Units), 2024-2032
Table 46. Roche Company Summary
Table 47. Roche Raibizumab Biosimilars Product Offerings
Table 48. Roche Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 49. Roche Key News & Latest Developments
Table 50. Novartis Company Summary
Table 51. Novartis Raibizumab Biosimilars Product Offerings
Table 52. Novartis Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 53. Novartis Key News & Latest Developments
Table 54. Genentech Company Summary
Table 55. Genentech Raibizumab Biosimilars Product Offerings
Table 56. Genentech Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 57. Genentech Key News & Latest Developments
Table 58. Pfizer Company Summary
Table 59. Pfizer Raibizumab Biosimilars Product Offerings
Table 60. Pfizer Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 61. Pfizer Key News & Latest Developments
Table 62. Sartorius Company Summary
Table 63. Sartorius Raibizumab Biosimilars Product Offerings
Table 64. Sartorius Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 65. Sartorius Key News & Latest Developments
Table 66. Eli Lilly Company Summary
Table 67. Eli Lilly Raibizumab Biosimilars Product Offerings
Table 68. Eli Lilly Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 69. Eli Lilly Key News & Latest Developments
Table 70. Bayer Company Summary
Table 71. Bayer Raibizumab Biosimilars Product Offerings
Table 72. Bayer Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 73. Bayer Key News & Latest Developments
Table 74. Amgen Company Summary
Table 75. Amgen Raibizumab Biosimilars Product Offerings
Table 76. Amgen Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 77. Amgen Key News & Latest Developments
Table 78. PlantForm Company Summary
Table 79. PlantForm Raibizumab Biosimilars Product Offerings
Table 80. PlantForm Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 81. PlantForm Key News & Latest Developments
Table 82. PharmaPraxis Company Summary
Table 83. PharmaPraxis Raibizumab Biosimilars Product Offerings
Table 84. PharmaPraxis Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 85. PharmaPraxis Key News & Latest Developments
Table 86. Samsung Bioepis Company Summary
Table 87. Samsung Bioepis Raibizumab Biosimilars Product Offerings
Table 88. Samsung Bioepis Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 89. Samsung Bioepis Key News & Latest Developments
Table 90. Centus Company Summary
Table 91. Centus Raibizumab Biosimilars Product Offerings
Table 92. Centus Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 93. Centus Key News & Latest Developments
Table 94. Cadila Pharmaceuticals Company Summary
Table 95. Cadila Pharmaceuticals Raibizumab Biosimilars Product Offerings
Table 96. Cadila Pharmaceuticals Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 97. Cadila Pharmaceuticals Key News & Latest Developments
Table 98. Dr Reddy's Company Summary
Table 99. Dr Reddy's Raibizumab Biosimilars Product Offerings
Table 100. Dr Reddy's Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 101. Dr Reddy's Key News & Latest Developments
Table 102. Aurobindo Pharma Company Summary
Table 103. Aurobindo Pharma Raibizumab Biosimilars Product Offerings
Table 104. Aurobindo Pharma Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 105. Aurobindo Pharma Key News & Latest Developments
Table 106. Biocad Company Summary
Table 107. Biocad Raibizumab Biosimilars Product Offerings
Table 108. Biocad Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 109. Biocad Key News & Latest Developments
Table 110. MAbxience Company Summary
Table 111. MAbxience Raibizumab Biosimilars Product Offerings
Table 112. MAbxience Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 113. MAbxience Key News & Latest Developments
Table 114. Hetero Company Summary
Table 115. Hetero Raibizumab Biosimilars Product Offerings
Table 116. Hetero Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 117. Hetero Key News & Latest Developments
Table 118. Biocon Company Summary
Table 119. Biocon Raibizumab Biosimilars Product Offerings
Table 120. Biocon Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 121. Biocon Key News & Latest Developments
Table 122. Kirin Biologics Company Summary
Table 123. Kirin Biologics Raibizumab Biosimilars Product Offerings
Table 124. Kirin Biologics Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 125. Kirin Biologics Key News & Latest Developments
Table 126. Mylan Company Summary
Table 127. Mylan Raibizumab Biosimilars Product Offerings
Table 128. Mylan Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 129. Mylan Key News & Latest Developments
Table 130. BeiGene Company Summary
Table 131. BeiGene Raibizumab Biosimilars Product Offerings
Table 132. BeiGene Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 133. BeiGene Key News & Latest Developments
Table 134. Innovent Company Summary
Table 135. Innovent Raibizumab Biosimilars Product Offerings
Table 136. Innovent Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 137. Innovent Key News & Latest Developments
Table 138. Qilu Pharmaceutical Company Summary
Table 139. Qilu Pharmaceutical Raibizumab Biosimilars Product Offerings
Table 140. Qilu Pharmaceutical Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 141. Qilu Pharmaceutical Key News & Latest Developments
Table 142. Hengrui Pharmaceuticals Company Summary
Table 143. Hengrui Pharmaceuticals Raibizumab Biosimilars Product Offerings
Table 144. Hengrui Pharmaceuticals Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 145. Hengrui Pharmaceuticals Key News & Latest Developments
Table 146. Hisun Pharmaceutical Company Summary
Table 147. Hisun Pharmaceutical Raibizumab Biosimilars Product Offerings
Table 148. Hisun Pharmaceutical Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 149. Hisun Pharmaceutical Key News & Latest Developments
Table 150. TOT BIOPHARM Company Summary
Table 151. TOT BIOPHARM Raibizumab Biosimilars Product Offerings
Table 152. TOT BIOPHARM Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 153. TOT BIOPHARM Key News & Latest Developments
Table 154. Luye Pharmaceutical Company Summary
Table 155. Luye Pharmaceutical Raibizumab Biosimilars Product Offerings
Table 156. Luye Pharmaceutical Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 157. Luye Pharmaceutical Key News & Latest Developments
Table 158. Henlius Company Summary
Table 159. Henlius Raibizumab Biosimilars Product Offerings
Table 160. Henlius Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 161. Henlius Key News & Latest Developments
Table 162. Raibizumab Biosimilars Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 163. Global Raibizumab Biosimilars Capacity Market Share of Key Manufacturers, 2021-2023
Table 164. Global Raibizumab Biosimilars Production by Region, 2018-2023 (K Units)
Table 165. Global Raibizumab Biosimilars Production by Region, 2024-2032 (K Units)
Table 166. Raibizumab Biosimilars Market Opportunities & Trends in Global Market
Table 167. Raibizumab Biosimilars Market Drivers in Global Market
Table 168. Raibizumab Biosimilars Market Restraints in Global Market
Table 169. Raibizumab Biosimilars Raw Materials
Table 170. Raibizumab Biosimilars Raw Materials Suppliers in Global Market
Table 171. Typical Raibizumab Biosimilars Downstream
Table 172. Raibizumab Biosimilars Downstream Clients in Global Market
Table 173. Raibizumab Biosimilars Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Raibizumab Biosimilars Segment by Type in 2022
Figure 2. Raibizumab Biosimilars Segment by Application in 2022
Figure 3. Global Raibizumab Biosimilars Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Raibizumab Biosimilars Market Size: 2022 VS 2032 (US$, Mn)
Figure 6. Global Raibizumab Biosimilars Revenue, 2018-2032 (US$, Mn)
Figure 7. Raibizumab Biosimilars Sales in Global Market: 2018-2032 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Raibizumab Biosimilars Revenue in 2022
Figure 9. By Type - Global Raibizumab Biosimilars Revenue, (US$, Mn), 2022 & 2032
Figure 10. By Type - Global Raibizumab Biosimilars Revenue Market Share, 2018-2032
Figure 11. By Type - Global Raibizumab Biosimilars Sales Market Share, 2018-2032
Figure 12. By Type - Global Raibizumab Biosimilars Price (K USD/Unit), 2018-2032
Figure 13. By Application - Global Raibizumab Biosimilars Revenue, (US$, Mn), 2022 & 2032
Figure 14. By Application - Global Raibizumab Biosimilars Revenue Market Share, 2018-2032
Figure 15. By Application - Global Raibizumab Biosimilars Sales Market Share, 2018-2032
Figure 16. By Application - Global Raibizumab Biosimilars Price (K USD/Unit), 2018-2032
Figure 17. By Region - Global Raibizumab Biosimilars Revenue, (US$, Mn), 2022 & 2032
Figure 18. By Region - Global Raibizumab Biosimilars Revenue Market Share, 2018 VS 2022 VS 2032
Figure 19. By Region - Global Raibizumab Biosimilars Revenue Market Share, 2018-2032
Figure 20. By Region - Global Raibizumab Biosimilars Sales Market Share, 2018-2032
Figure 21. By Country - North America Raibizumab Biosimilars Revenue Market Share, 2018-2032
Figure 22. By Country - North America Raibizumab Biosimilars Sales Market Share, 2018-2032
Figure 23. US Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 24. Canada Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 25. Mexico Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 26. By Country - Europe Raibizumab Biosimilars Revenue Market Share, 2018-2032
Figure 27. By Country - Europe Raibizumab Biosimilars Sales Market Share, 2018-2032
Figure 28. Germany Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 29. France Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 30. U.K. Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 31. Italy Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 32. Russia Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 33. Nordic Countries Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 34. Benelux Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 35. By Region - Asia Raibizumab Biosimilars Revenue Market Share, 2018-2032
Figure 36. By Region - Asia Raibizumab Biosimilars Sales Market Share, 2018-2032
Figure 37. China Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 38. Japan Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 39. South Korea Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 40. Southeast Asia Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 41. India Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 42. By Country - South America Raibizumab Biosimilars Revenue Market Share, 2018-2032
Figure 43. By Country - South America Raibizumab Biosimilars Sales Market Share, 2018-2032
Figure 44. Brazil Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 45. Argentina Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 46. By Country - Middle East & Africa Raibizumab Biosimilars Revenue Market Share, 2018-2032
Figure 47. By Country - Middle East & Africa Raibizumab Biosimilars Sales Market Share, 2018-2032
Figure 48. Turkey Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 49. Israel Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 50. Saudi Arabia Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 51. UAE Raibizumab Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 52. Global Raibizumab Biosimilars Production Capacity (K Units), 2018-2032
Figure 53. The Percentage of Production Raibizumab Biosimilars by Region, 2022 VS 2032
Figure 54. Raibizumab Biosimilars Industry Value Chain
Figure 55. Marketing Channels
